Ridaura

Active Ingredient(s): Auranofin
FDA Approved: * May 24, 1985
Pharm Company: * PROMETHEUS LABS
Category: Arthritis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ridaura Overview

Auranofin is a gold complex classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura. Contents 1 Use 2 Research 2.1 HIV infection 2.2 Amebiasis 2.3 Tuberculosis 2.4 Ovarian cancer 3 References 4 Further reading 5 External links Use Auranofin is used to treat rheumatoid arthritis. It improves arthritis symptoms including painful or tender and swollen joints and morning stiffness.[3] Auranofin is a safer treatment compared...

Read more Ridaura Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Auranofin

Recent Ridaura Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Auranofin
  • Capsule: 3mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ridaura: (2 results)

Sorted by National Drug Code
  • 54766-093 Ridaura 3 mg Oral Capsule by Sebela Pharmaceuticals Inc.
  • 65483-093 Ridaura 3 mg Oral Capsule by Prometheus Laboratories Inc.

Other drugs which contain Auranofin or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA